N/A
N=80
Lidocaine and Pain Management in First Trimester Abortions
Pain
Bottom Line
View on ClinicalTrials.gov: NCT00613821 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: The Effects of an Intrauterine Lidocaine Infusion to Standard Paracervical Block on Decreasing Patient Pain Measured by Visual Analog Scale in First Trimester Abortions. — 71; 43 mm
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Lidocaine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Oregon Health and Science University
- Primary completion
- May 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Effects of an Intrauterine Lidocaine Infusion to Standard Paracervical Block on Decreasing Patient Pain Measured by Visual Analog Scale in First Trimester Abortions. |
71; 43 | — |
Summary
The purpose of this study is to examine the effect of lidocaine (a numbing medication) inside the uterus on patient pain during an early abortion, compared to the paracervical block (lidocaine injected on either side of the cervix).
Eligibility Criteria
Inclusion Criteria
- Good general health
- Age>18years
- English speaking
- Voluntarily requesting pregnancy termination
- Have an estimated gestation of up to 76 days since the first day of the preceding menstrual period
- Confirmed by ultrasound
- Be able and willing to sign an informed consent
- Agree to the terms of the study
- All patients must be premedicated with Ibuprofen and Valium (per clinic protocols)
Exclusion Criteria
- Significant physical or mental health condition
- A gestational age of 77 days or more
- Adnexal mass or tenderness on pelvic exam consistent with pelvic inflammatory disease
- Patients who require or request IV/intramuscular sedation
- Patients who refuse Ibuprofen, Valium and/or paracervical blocks
- Patients allergic to lidocaine
- Patients with known hepatic disease
- Patients weighing less than 100 lbs
Data sourced from ClinicalTrials.gov (NCT00613821). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.